Monoclonal Antibodies In Veterinary Health Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type (Dogs, Others), By Application (Dermatology, Pain, Others), End-User (Veterinary Hospitals, Others), By Region, & Competition, 2020-2030F

Market Overview

Global Monoclonal Antibodies In Veterinary Health Market was valued at USD 903.40 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 15.50% through 2030. The global monoclonal antibodies (mAbs) in veterinary health market represents a rapidly growing segment within the broader animal healthcare industry. Monoclonal antibodies, which are lab-engineered antibodies that can target specific antigens, are increasingly being adopted in veterinary medicine for their therapeutic and diagnostic applications.

Key Market Drivers

Increasing Companion Animal Ownership and Pet Humanization

The increasing trend of companion animal ownership, coupled with the growing humanization of pets, is a major driver of the Global Monoclonal Antibodies (mAbs) in the Veterinary Health Market. Over 50% of the global population is estimated to own a pet, with dogs being the most prevalent, found in approximately 33% of households worldwide. Cats are the second most popular choice, owned by nearly 25% of pet-keeping households. This widespread pet ownership trend reflects a significant and growing market opportunity for pet-related industries, including food, healthcare, accessories, and services, driven by increasing consumer demand and the human-animal bond. As pet owners demand higher-quality healthcare solutions for their animals, the market for advanced veterinary therapeutics, including monoclonal antibody-based treatments, is experiencing significant growth.

Households in the U.S., EU, and China collectively own over 500 million dogs and cats, underscoring a massive and expanding market for pet healthcare solutions. In the U.S., pet ownership grew from 68% of households in 2016 to 70% in 2021, reflecting a sustained upward trend in companion animal adoption and increased consumer spending on veterinary care. Over the past decade, there has been a significant increase in pet adoption rates, particularly in developed economies such as North America, Europe, and parts of Asia-Pacific. Factors such as rising disposable incomes, changing lifestyles, and a growing preference for emotional companionship have contributed to this trend. With pet ownership on the rise, there is a corresponding increase in demand for effective veterinary treatments, including monoclonal antibodies for conditions such as arthritis, dermatological disorders, and cancer.

In the Asia-Pacific region, particularly China, pet humanization is a dominant trend, with 55% of pet owners treating their cats and dogs as their own children. Additionally, 28% regard them as integral family members, while 7.5% view them as close companions. This shift in pet ownership dynamics is driving demand for premium veterinary care and advanced therapeutic solutions. The concept of pet humanization, where pets are treated as family members, is reshaping the veterinary healthcare landscape. Pet owners are increasingly willing to invest in high-quality medical treatments similar to human healthcare, including advanced biologics and immunotherapies. Greater awareness and acceptance of monoclonal antibodies as an effective, targeted therapy. A surge in veterinary visits and demand for specialized treatments. Increased pet insurance coverage, making costly therapies more accessible to pet owners. With longer pet lifespans, there is a growing prevalence of chronic diseases such as osteoarthritis, atopic dermatitis, cancer, and autoimmune disorders. Traditional treatment options like steroids and NSAIDs come with potential side effects, making monoclonal antibody-based therapies an attractive alternative due to their targeted action, reduced toxicity, and longer-lasting effects.

Rising Prevalence of Animal Diseases and Zoonotic Infections

The increasing incidence of animal diseases and zoonotic infections has become a significant driver of growth in the Global Monoclonal Antibodies (mAbs) in Veterinary Health Market. Globally, zoonotic diseases account for approximately one billion illnesses and millions of fatalities annually. Additionally, 60% of newly emerging infectious diseases worldwide originate from animals, highlighting the critical need for advanced veterinary and public health interventions. As the risk of infectious outbreaks and chronic diseases in animals rises, the demand for targeted, effective, and safe treatment options such as monoclonal antibodies continues to grow. This trend is shaping the veterinary pharmaceutical landscape, influencing regulatory policies, and accelerating investments in veterinary biotechnology. The veterinary sector is witnessing a surge in infectious diseases affecting companion animals, livestock, and poultry. Factors such as climate change, urbanization, and global trade in animals have increased the transmission of viruses, bacteria, parasites, and fungi among animals. Canine distemper, parvovirus, and atopic dermatitis in companion animals. Bovine respiratory disease (BRD), mastitis, and foot-and-mouth disease (FMD) in livestock. Newcastle disease and avian influenza in poultry. Monoclonal antibodies offer a highly specific mechanism of action, making them an attractive alternative to conventional antibiotics and steroids, particularly in cases where antimicrobial resistance (AMR) is a concern.

Zoonotic diseases—those transmitted between animals and humans—are a growing global health threat, prompting increased focus on veterinary disease management. The World Health Organization (WHO) and the World Organisation for Animal Health (WOAH) have emphasized the need for better preventive and therapeutic solutions to control zoonotic outbreaks. Rabies, brucellosis, leptospirosis, and anthrax from domestic and farm animals. Influenza strains and coronaviruses originating from livestock and poultry. Monoclonal antibodies serve as a proactive approach to managing zoonotic diseases by offering precise, pathogen-specific treatment, reducing disease spread, and minimizing the need for excessive antibiotic use.

Download Free Sample Report

Key Market Challenges

High Development Costs

Developing monoclonal antibodies is a complex and expensive process. Research and development costs can be prohibitively high, which poses a significant challenge for smaller biotech companies and startups looking to enter the market. These high costs can limit the diversity of players and the range of mAb products available.

Lengthy Regulatory Processes

Regulatory approvals for veterinary monoclonal antibodies can be time-consuming and rigorous. Companies must demonstrate safety, efficacy, and quality before their products can reach the market. The lengthy regulatory processes can delay the availability of new therapies and deter investment in research and development.

Limited Awareness and Adoption

While the awareness of monoclonal antibodies in veterinary health is growing, there is still a need for education and outreach. Many veterinarians and pet owners may not be fully aware of the potential benefits of mAbs or may not understand how they can be integrated into existing treatment plans. Raising awareness and promoting adoption is an ongoing challenge.

Key Market Trends

Expansion of Targeted Therapies

One of the most significant upcoming trends is the expansion of targeted therapies using monoclonal antibodies. As our understanding of animal diseases and their molecular mechanisms deepens, researchers are developing mAbs that can target specific disease pathways with precision. This trend promises to provide veterinarians with a broader range of effective treatment options for a variety of conditions.

Diagnostic Monoclonal Antibodies

The use of mAbs for diagnostic purposes is an emerging trend in veterinary healthcare. Diagnostic monoclonal antibodies are designed to detect specific antigens or markers associated with diseases or health conditions in animals. These innovative tools enable earlier and more accurate disease detection, enhancing the overall diagnostic capabilities of veterinarians.

Collaborative Research Initiatives

The veterinary healthcare industry is witnessing an increase in collaborative research initiatives between biotech companies, academic institutions, and veterinary professionals. These collaborations foster knowledge exchange, accelerate research and development, and pave the way for innovative mAb therapies. As interdisciplinary collaboration continues to grow, so does the potential for groundbreaking discoveries.

Adoption of Biosimilars

Biosimilars, which are highly similar versions of existing approved mAbs, are gaining traction in the veterinary health market. These cost-effective alternatives to branded monoclonal antibodies are becoming more readily available, offering veterinarians and pet owners more affordable treatment options without compromising quality or efficacy.

Segmental Insights

Animal Type Insights

Based on the category of Animal Type, the dog segment holds the dominant market share, driven by high pet ownership rates, increasing prevalence of chronic canine diseases, rising healthcare expenditures, and growing demand for advanced veterinary therapeutics. The expansion of monoclonal antibody applications for dogs, particularly in treating inflammatory, autoimmune, and infectious diseases, has further solidified this segment’s leadership in the market. Dogs are the most widely owned companion animals worldwide, particularly in developed markets such as North America, Europe, and Asia-Pacific.

As of 2024, 66% of U.S. households—equivalent to 86.9 million homes—own at least one pet, marking a significant increase from 56% in 1988. This steady growth reflects the deepening role of pets in households, extending beyond companionship to emotional and psychological well-being. Notably, 97% of pet owners classify their pets as family members, underscoring a strong consumer preference for premium veterinary care and advanced pet health solutions.

In China and other Asia-Pacific markets, pet humanization trends have surged, with dogs increasingly regarded as family members, driving higher spending on advanced treatments. This widespread dog ownership translates into a large addressable market for monoclonal antibody therapies, as pet owners seek targeted and long-lasting treatment solutions. The increasing incidence of chronic and inflammatory conditions in dogs has fueled the demand for monoclonal antibody-based treatments as a safer and more effective alternative to traditional therapies.

Application Insights

Based on the category of Application, The dermatology segment is experiencing the fastest growth within the Global Monoclonal Antibodies (mAbs) in Veterinary Health Market, driven by rising cases of atopic dermatitis and allergic skin conditions, increased pet owner awareness, and the superior efficacy of monoclonal antibodies over traditional treatments. As the demand for targeted, long-lasting, and side-effect-free therapies continues to rise, veterinary dermatology is emerging as a key focus area for pharmaceutical companies and veterinarians. Skin disorders, particularly canine atopic dermatitis (CAD) and allergic skin diseases, are among the most common reasons for veterinary visits worldwide. Atopic dermatitis is a widespread dermatological condition in dogs, characterized by chronic itching (pruritus) and inflammation. It is estimated to affect 10-15% of the global canine population, making it a significant concern in veterinary healthcare and a key driver of demand for advanced dermatological treatments.

Feline allergic dermatitis and pruritic conditions are also increasing, necessitating advanced therapeutic options beyond steroids and antihistamines. The widespread nature of these conditions has led to a significant market opportunity for monoclonal antibody-based dermatological treatments. Traditional treatments for veterinary dermatological conditions include corticosteroids, cyclosporine, and antihistamines. However, these options often lead to immunosuppression, liver toxicity, and short-term relief, limiting their long-term use.

Download Free Sample Report

Regional Insights

Based on region, The North American region holds the largest share of the Global Monoclonal Antibodies (mAbs) in Veterinary Health Market, driven by high pet ownership rates, increasing veterinary healthcare expenditure, advanced R&D capabilities, and a strong regulatory framework. The region benefits from the early adoption of biologic therapies, the presence of key market players, and growing demand for specialized veterinary care. The region boasts a well-established and sophisticated veterinary healthcare system, including specialized clinics, diagnostic centers, and research institutions. This infrastructure supports the adoption of cutting-edge treatments like monoclonal antibodies, which require precise administration and monitoring.

North America is home to leading pharmaceutical and biotechnology companies that are heavily invested in veterinary health innovation. These companies are at the forefront of developing and commercializing monoclonal antibody therapies, leveraging their expertise in human healthcare to create targeted treatments for animals. Regulatory bodies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, have established clear pathways for the approval of veterinary biologics, including monoclonal antibodies. This streamlined regulatory environment accelerates the introduction of new therapies to the market.

Recent Developments

• In January 2024, Elanco Animal Health Incorporated introduced a strategic, multi-year initiative aimed at reducing mortality from canine parvovirus (parvo), a highly contagious and often fatal disease. The "Defend Puppies. Defeat Parvo." campaign seeks to prevent unnecessary deaths by protecting 1 million puppies from the virus, which has a mortality rate of up to 91% if not treated promptly and aggressively.
• In January 2022, Zoetis received approval from the U.S. FDA for Solensia, a product designed to manage pain associated with osteoarthritis in cats.
• In January 2022, Boehringer Ingelheim International GmbH announced a collaboration with MabGenesis, a privately held biopharmaceutical firm based in Japan. This collaborative effort is focused on the development of monoclonal antibodies for the treatment of canine diseases. 

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco LLC
• Boehringer Ingelheim GmbH
• Indian Immunologicals Ltd
• Virbac SA

Report Scope:

In this report, the Global Monoclonal Antibodies In Veterinary Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Monoclonal Antibodies In Veterinary Health Market, By Animal Type:

o   Dogs

o   Others

• Monoclonal Antibodies In Veterinary Health Market, By Application:

o   Dermatology

o   Pain

o   Others

• Monoclonal Antibodies In Veterinary Health Market, By End-User:

o   Veterinary Hospitals

o   Others

• Monoclonal Antibodies In Veterinary Health Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibodies In Veterinary Health Market.

Available Customizations:

Global Monoclonal Antibodies In Veterinary Health market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).